Wednesday June 5, 2019
electroCore (ECOR)
Continuing Execution of the Redeployment Plan
Electrocore Inc is a commercial-stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology and rheumatology. Its product gammaCore is FDA-cleared for the acute treatment of pain associated with migraine and episodic cluster headache in adults.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
Founder and Chief Science and Strategy Officer departs. electroCore announced another event as part of the redeployment plan that emerged on May 29. Founder Joseph P. Enrico, who served as the Company’s Chief Science and Strategy Officer, agreed to leave the company, effective as of June 8, 2019. He co-founded the company in 2005 and served in multiple roles including Chief Executive Officer (CEO) prior taking his current role in 2016. He remains as a Board Director and holds 2.2% equity stake in the company.
Chief Medical Officer to take over the strategy role. Management stated plans to continue with the current leadership team. Tony Fiorino, M.D. Ph.D. will continue to serve as Chief…
Get full report on Channelchek desktop.
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.